Friday, December 11, 2020, 8:30 AM - 5:00 PM


Activity Learning Objectives 1) Understand the epidemiology and disparities of liver cancer in the US. 2) Review the current role of surgical and loco-regional treatments for liver cancer. 3) Critical review of molecular therapies and SBRT in the management of advanced HCC 4) Understand the molecular rationale for immune therapies in HCC.

1. I am able to understand the epidemiology, risk factors and clinical indications for treatment of liver cancer according to guidelines.
2. I am able to understand the management of COVID 19 liver cancer.
3. I am able to understand the mechanism of action of novel targeted therapies and immune therapies coming for the management of these diseases.
4. I am able to analyze the prospects of novel therapies (combination therapies and radiation therapy) in the management of liver cancer.

This activity is complimentary:

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (7.00 hours)

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Friday, December 11, 2020

This activity is made possible in part by educational grants from:

Bristol-Myers Squibb

Celsion

Eisai

Exelixis

Merck & Co.